European Health AI Oversight Shifts Toward Continuous Monitoring
European and UK regulators are moving from static approvals to continuous lifecycle monitoring for healthcare AI under the EU AI Act and medical device rules. AI captured 48% of European health venture funding in 2026, up from 22% in 2025, amid major deals such as GE HealthCare’s $945 million acquisition of SOFIE Biosciences. The roundup also covers cross-border clinical pilots, sovereign compute initiatives, and digital twins entering hospital workflows.
UK regulators are advancing an international reliance pathway so clearances from trusted agencies such as the FDA and Australia’s TGA can speed domestic review. In the EU, device makers are adopting lifecycle-based oversight to manage overlapping obligations under the AI Act and MDR/IVDR.
Investment data show AI-focused firms took 48% of European health venture funding in 2026, nearly double 2025’s 22%. Consonance closed a $1.35 billion fund, while GE HealthCare agreed to buy SOFIE Biosciences for $945 million.
Continuous oversight could give patients and clinicians more confidence that health AI remains safe after approval, while catching performance drift sooner. Yet lifecycle monitoring may add compliance work, potentially straining smaller medtech developers and influencing which tools reach hospitals. As AI absorbs more venture funding, adoption may accelerate in diagnostics and workflow support, but benefits could vary if market power concentrates or oversight capacity lags.